Modulation of Monocyte-Driven Myositis in Alphavirus Infection Reveals a Role for CX3CR1+ Macrophages in Tissue

Ali Zaid1,2,3, Kothila Tharmarajah4,2,3, Helen Mostafavi4,2,3

  • 1Menzies Health Institute Queensland, Griffith University, Southport, Queensland, Australia a.zaid@griffith.edu.au s.mahalingam@griffith.edu.au.

Mbio
|March 5, 2020
PubMed

Insights

Immune-modifying microparticles (IMP) reduced muscle damage and inflammation from Ross River virus infection by modulating inflammatory monocytes and promoting tissue repair macrophages.

Area of Science:

  • Immunology
  • Virology
  • Pathology

Background:

  • Arthritogenic alphaviruses like Ross River virus (RRV) cause severe muscle and joint pain, with immune responses poorly understood.
  • Current treatments for alphavirus-induced inflammation are limited to palliative care.

Purpose of the Study:

  • To elucidate the host immune response dynamics during alphavirus-induced myositis.
  • To investigate the therapeutic potential of immune-modifying microparticles (IMP) in alphavirus infection.

Main Methods:

  • Induction of myositis in a mouse model using Ross River virus (RRV).
  • Characterization of immune cell populations, specifically monocytes and macrophages, in infected muscle.
  • Administration of immune-modifying microparticles (IMP) to modulate monocyte migration.
  • Assessment of disease severity, tissue damage, inflammation, and immune cell accumulation.

Main Results:

  • RRV-induced myositis was driven by CD11bhi Ly6Chi inflammatory monocytes.
  • Recovery was associated with the accumulation of CD11bhi Ly6Clo CX3CR1+ macrophages in the muscle.
  • IMP treatment reduced disease scores, tissue damage, and inflammation.
  • IMP promoted the accumulation of CX3CR1+ macrophages, enhancing tissue recovery.

Conclusions:

  • Muscle macrophage subsets play a critical role in alphavirus-induced myositis and subsequent tissue repair.
  • IMP represent a promising immunomodulatory strategy to mitigate alphavirus-induced inflammation and promote recovery.
  • Targeting key immune cell effectors with microparticles can shift disease outcomes towards tissue repair.

Related Concept Videos